Drug intelligence / Profile preview

4HF-06

Development stage: Preclinical
Lead developer: 4HF Biotec
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

4HF-06 is an early-stage small molecule drug conjugate (SMDC) being developed by 4HF Biotec for the treatment of small cell lung cancer (SCLC). The drug is designed using 4HF Biotec's proprietary AI and data mining platform, which identifies specific cancer targets to enable precision medicine. As an SMDC, 4HF-06 is engineered to consist of a targeting ligand conjugated to a therapeutic payload, intended to deliver the agent specifically to SCLC cells while minimizing systemic toxicity. It is currently in the discovery phase, specifically undergoing in silico chemistry and medicinal chemistry optimization.

Beyond the preview

Go deeper on 4HF-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4HF-06.

Explore the full profile